A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas

Inclusion Criteria:

   - Adult participants, >/= 18 years of age

   - Participants with multiple basal cell carcinomas, including participants with Gorlin
   syndrome, with at least 6 clinically evident basal cell carcinomas at the time of
   randomization, of which 3 measure 5 mm or more in diameter and are considered target
   lesions. All other lesions are considered to be non-target lesions

   - Histopathologic confirmation that at least one of the three target lesions is basal
   cell carcinoma

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

   - Adequate renal and hepatic function and hematopoietic capacity

   - Women of childbearing potential must agree to use contraception as defined by protocol
   during treatment and for at least 9 months after completion of study treatment

   - Male participants with female partners of childbearing potential must agree to use
   contraception as defined by protocol during treatment and for 2 months after
   completion of study treatment

Exclusion Criteria:

   - Inability or unwillingness to swallow capsules

   - Pregnant or breastfeeding women

   - Any metastatic basal cell carcinoma

   - Locally advanced basal cell carcinoma lesion that is considered to be inoperable or to
   have medical contraindications to surgery

   - Recent (i.e., within the past 28 days prior to randomization) or current participation
   in another experimental drug study

   - Known or suspected alcohol abuse

   - One of the following known rare hereditary conditions: galactose intolerance, primary
   hypolactasia or glucose-galactose malabsorption